A biomarker discovery workflow investigates measurable characteristics that could inform a biological or clinical question. After your study identifies candidates, a practical problem remains: which findings support your proposed use, and which concern a different population, specimen, or measurement? The next step is to turn those differences into clear validation questions.
This article focuses on that transition: from a candidate finding to a defined evidence and validation question. Patsnap Open’s Pharma Intelligence MCP server brings literature and related research records into a supported Claude Desktop or Codex setup for review alongside the team’s candidate findings and intended use.
Where evidence review fits in discovery
A useful way to organize the work is to distinguish four stages:
| Stage | Question being addressed | Deliverable |
|---|---|---|
| Define the research use | What decision or biological question should the measurement inform? | A stated purpose and study context |
| Generate candidate findings | Which measured characteristics warrant investigation? | Discovery results with their study conditions |
| Review candidate evidence | What supports each candidate, and where are the gaps? | A candidate-specific evidence assessment |
| Plan and conduct validation | Does the measurement perform adequately for the proposed use? | Evidence evaluated against defined requirements |
Teams can revisit the evidence as new findings emerge, and earlier reviews can also inform discovery design. Here, the focus is the review of candidates already identified. The study design and validation work depend on the biomarker and its intended use.
The FDA–NIH BEST resource distinguishes analytical validation, concerning whether the test measures what it is intended to measure, from clinical validation, concerning its relationship to the relevant clinical concept. Exploratory or discovery data alone are generally insufficient to complete that validation.
Literature review can inform both questions, but it cannot replace the required measurements and studies.
Specify the claim before collecting more papers
State what the candidate is supposed to indicate, in which setting, and how it is measured. For example, a marker proposed to predict treatment response raises a different evidence question from one used to track disease progression.
Capture five elements:
- Candidate identity: the marker, variant, panel, or measured feature under investigation.
- Purpose: the specific question the result is intended to answer.
- Population: the disease setting and participants relevant to that purpose.
- Measurement context: specimen, assay or measurement method, and timing.
- Current finding: what your discovery work or initial source actually reported.
These details guide inclusion decisions. A paper discussing the same marker in a different specimen or disease setting may be informative, but the difference should remain visible in the assessment.
Read evidence at the study level
Organize the review around studies and their conditions, not the number of search hits. For each relevant record, identify the study question, population, measurement, reported finding, and limitations that affect interpretation.
A working assessment can use these review questions:
| Evidence question | Information to inspect |
|---|---|
| Was the same candidate measured? | Marker definition, assay target, and any panel composition |
| Was it studied in the relevant setting? | Population, specimen, timing, and disease context |
| What was reported? | The measured relationship or performance result, with its stated uncertainty |
| How was the finding checked? | Validation data or independent assessment described by the study |
| What remains unresolved? | Missing methods, differing conditions, or unanswered questions about the proposed use |
Where an abstract does not provide the required methods or results, make full-text review a specific next action. Ask the assistant to identify missing information rather than infer it.
Use trial and drug-development records when they help explain the research setting. Include patents when the question concerns an assay or technical implementation. Each source should have a reason to be in the assessment.
Use AI to organize the review around your candidates
An assistant can help extract explicitly reported information, group records by question, and prepare a structured summary for review. The useful input is the candidate brief plus your inclusion criteria and any project material you choose to provide.
Pharma Intelligence MCP gives an AI application access to Patsnap research-data tools. Its documented scope includes literature, targets, drugs, and clinical-trial information. Model Context Protocol (MCP) supplies the tool connection; an assistant such as Claude Desktop or Codex with MCP support uses those tools within the research conversation.
For biomarker work, the value is being able to follow a candidate into relevant research and development records while keeping the team’s intended use in view. Supply that context explicitly; connecting a server does not by itself tell the assistant what your study is trying to establish.
Try the review with one of your candidates. After connecting Pharma Intelligence MCP in Claude or Codex, replace the three bracketed fields and provide the study context described above:
Candidate: [marker or panel]. Intended use: [the question the measurement should answer]. Specimen: [planned specimen].
Use my study brief and the connected research tools to find relevant studies. For each study, capture the population, specimen, measurement method, reported finding, and available validation information. Identify conflicting or missing evidence and retain the source reference. Keep analytical performance and clinical relevance separate.
Start by reviewing one returned study against your intended use before expanding to the rest of the candidates.
Produce a validation handoff
The review should end with an actionable question for each candidate. “More research is needed” is too broad to guide the next study.
Illustrative handoff: your team plans to measure a candidate in plasma, but the reviewed study measured it in tissue. The candidate name matches; the measurement context does not.
- What the source supports: a finding in the tissue and study setting it actually examined.
- What remains open: whether the candidate can be measured reliably and interpreted for the proposed use in plasma.
- Next study-team question: what analytical and clinical evidence is needed for that specimen and intended use?
Apply this handoff to one candidate in your own brief: attach the source, name the context mismatch, and write the question the study team needs to resolve. A study in another specimen should remain evidence for the setting it examined.
Take your biomarker research further
Explore life sciences data APIs and MCP tools on Patsnap Open to support the research questions around your biomarker candidates.
Frequently asked questions
How does biomarker discovery differ from validation?
Discovery identifies candidates worth investigating. Validation evaluates a test and its interpretation for a specified purpose, including the relevant analytical and clinical evidence.
Can AI validate a biomarker?
AI can assist with evidence retrieval and organization. Establishing validity requires the measurements, studies, and evaluation appropriate to the intended use.
Should every biomarker review include patents?
Include them when assay design, technical implementation, or related intellectual property is part of the research question. They do not need to appear in every candidate review.
Sources and disclosure
Published by Patsnap. Definitions and product descriptions follow the linked sources, reviewed September 11, 2026. The workflow and handoff example are illustrative; this article does not report a biomarker discovery study or validation result.